Sorry, you need to enable JavaScript to visit this website.

A study to see if enzalutamide could help patients with prostate cancer have more time before their cancer starts to spread to other parts of the body or dying from any cause

PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer

Category & Conditions: Cancer
Medicine: Xtandi (enzalutamide) Identifier (NCT): NCT02003924
Protocol ID: C3431005
Open Plain Language Summary Result: Click here